ANTX
AN2 Therapeutics, Inc.
$4.50
-0.13 (-2.81%)
At close · Jul 10
Market Cap
$162.07M
Shares
36,016,161
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$35.17M
+31.5%
FY2025
Diluted EPS
-$1.16
+32.6%
FY2025
Operating Cash Flow
-$29.83M
+39.4%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| $23.82M | $24.77M | $40.49M | $54.87M | $28.51M | $16.16M | |
| $13.3M | $13.34M | $14.07M | $14.76M | $12.75M | $4.67M | |
| — | — | $2.23M | — | — | — | |
| $37.12M | $38.11M | $56.79M | $69.64M | $42.26M | $21.57M | |
| -$37.12M | -$38.11M | -$56.79M | -$69.64M | -$42.26M | -$21.57M | |
| $2.57M | $2.93M | $5.47M | $4.86M | — | — | |
| — | $1000 | $1000 | $43K | $1.31M | -$38K | |
| — | $0 | $0 | $0 | $0 | $0 | |
| -$34.55M | -$35.17M | -$51.32M | -$64.73M | -$40.96M | -$21.54M | |
| -$34.55M | -$35.17M | -$51.32M | -$64.73M | -$42.78M | -$28.06M | |
| -$34.61M | -$35.15M | -$51.57M | -$64.08M | -$41.3M | -$21.57M | |
| USD/shares | — | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |
| USD/shares | — | -$1.16 | -$1.72 | -$2.74 | -$2.79 | -$10.64 |
| shares | — | 30.22M | 29.83M | 23.6M | 15.34M | 2.64M |
| shares | — | 30.22M | 29.83M | 23.6M | 15.34M | 2.64M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Biotechnology median 8.05×
EV/EBIT
—
Biotechnology median 25.73×
P/E (TTM)
—
Biotechnology median 7.52×